

MARKET BULLETIN

23 January 2024

NGXREG/LRD/MB4/24/01/18

Suspension of Trading on the Shares of Glaxo SmithKline Consumer Nigeria Plc

Trading Licence Holders are hereby notified that following the approval of the Scheme of Arrangement Glaxo SmithKline Consumer Nigeria Plc (the Company) between Glaxo SmithKline Consumer Nigeria Plc and holders of its fully paid ordinary shares by the Securities and Exchange Commission and sanctioning of the Scheme of Arrangement by the Federal High Court, trading in the Shares of the Company was suspended on the Nigerian Exchange Limited on Monday, 22 January 2024.

The suspension was to prevent further trading on the shares of the Company given that the effective date of the scheme of Arrangement was Friday, 19 January 2024, being the day the Court Sanction was filed with the Corporate Affairs Commission and to enable the Registrars to update the register of members for payment of the Scheme consideration and eventual delisting of the Company from the NGX.

This is for your information and records update, please.



Godstime Iwenekhai,
Head, Listings Regulation Department

This document is classified as: **DC3 - Authorised Use Only – CONFIDENTIAL USE**

Nigerian Exchange Group House, 2/4 Customs Street | PO Box 2457, Marina, Lagos, Nigeria | T +234 1 4638333 5 | M +234 700 225 5673 | E contactcenter@ngxgroup.com

Board of Directors

Chairperson: Dr. Salamatu Suleiman | **MD/CEO:** Ms. Tinuade Awe | **Independent Non-Executive Directors:** Mr. Chris Chukwu, Mr. Edo- Abasi Ukpung, Mrs. Amina Mohammed.

| **Non-Executive Directors:** Mr. Ebilate Mac- Yoroki, Mr. Olufemi .A. Akinsanya.

NGX Regulation Limited

www.ngxgroup.com